Erica Seiguer Shenoy, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Penicillins | 16 | 2020 | 404 | 4.260 |
Why?
|
Drug Hypersensitivity | 20 | 2020 | 903 | 4.140 |
Why?
|
Infection Control | 17 | 2024 | 984 | 3.510 |
Why?
|
Cross Infection | 14 | 2024 | 1427 | 2.540 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 9 | 2017 | 705 | 2.220 |
Why?
|
Anti-Bacterial Agents | 26 | 2024 | 7475 | 2.210 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 5 | 2022 | 249 | 2.110 |
Why?
|
Staphylococcal Infections | 10 | 2016 | 1396 | 1.710 |
Why?
|
beta-Lactams | 6 | 2019 | 158 | 1.470 |
Why?
|
Health Personnel | 8 | 2024 | 3384 | 1.470 |
Why?
|
Occupational Exposure | 3 | 2023 | 1807 | 1.210 |
Why?
|
Communicable Diseases | 5 | 2024 | 872 | 1.150 |
Why?
|
Masks | 2 | 2020 | 212 | 1.150 |
Why?
|
Occupational Health | 3 | 2021 | 812 | 1.060 |
Why?
|
Pandemics | 14 | 2024 | 8734 | 1.010 |
Why?
|
Patient Isolation | 2 | 2024 | 101 | 1.010 |
Why?
|
Enterococcus | 3 | 2017 | 158 | 0.980 |
Why?
|
Organizational Policy | 3 | 2021 | 434 | 0.970 |
Why?
|
Communicable Disease Control | 3 | 2020 | 857 | 0.900 |
Why?
|
Carbapenems | 2 | 2022 | 125 | 0.880 |
Why?
|
Post-Exposure Prophylaxis | 2 | 2022 | 113 | 0.880 |
Why?
|
Bedding and Linens | 1 | 2023 | 41 | 0.830 |
Why?
|
Hospitals, General | 3 | 2021 | 804 | 0.820 |
Why?
|
Gram-Positive Bacterial Infections | 3 | 2014 | 340 | 0.790 |
Why?
|
Bacteriological Techniques | 2 | 2014 | 277 | 0.790 |
Why?
|
Penile Diseases | 1 | 2022 | 47 | 0.790 |
Why?
|
Equipment Contamination | 2 | 2023 | 183 | 0.780 |
Why?
|
Cephalosporins | 4 | 2019 | 200 | 0.780 |
Why?
|
Disinfection | 1 | 2023 | 207 | 0.760 |
Why?
|
Gene Transfer, Horizontal | 1 | 2022 | 148 | 0.750 |
Why?
|
Anthozoa | 1 | 2021 | 65 | 0.740 |
Why?
|
Methicillin | 4 | 2017 | 62 | 0.740 |
Why?
|
Sequence Analysis | 1 | 2021 | 240 | 0.740 |
Why?
|
Exanthema | 2 | 2024 | 502 | 0.730 |
Why?
|
Hemorrhagic Fevers, Viral | 1 | 2021 | 23 | 0.730 |
Why?
|
Rectal Diseases | 1 | 2022 | 141 | 0.730 |
Why?
|
Skin Ulcer | 1 | 2022 | 131 | 0.730 |
Why?
|
Guideline Adherence | 4 | 2023 | 2233 | 0.720 |
Why?
|
Asymptomatic Infections | 2 | 2021 | 136 | 0.720 |
Why?
|
Skin Tests | 10 | 2020 | 630 | 0.710 |
Why?
|
Disease Outbreaks | 7 | 2024 | 1761 | 0.710 |
Why?
|
Travel Medicine | 1 | 2020 | 83 | 0.680 |
Why?
|
Communicable Diseases, Emerging | 2 | 2024 | 149 | 0.670 |
Why?
|
Delphi Technique | 1 | 2024 | 892 | 0.660 |
Why?
|
Acinetobacter Infections | 1 | 2020 | 74 | 0.660 |
Why?
|
Coronavirus Infections | 4 | 2020 | 3110 | 0.660 |
Why?
|
Urinalysis | 1 | 2021 | 369 | 0.650 |
Why?
|
Urologic Diseases | 1 | 2021 | 246 | 0.630 |
Why?
|
Duodenoscopes | 1 | 2019 | 43 | 0.630 |
Why?
|
Surgical Wound Infection | 2 | 2018 | 1547 | 0.630 |
Why?
|
Acinetobacter baumannii | 1 | 2020 | 125 | 0.620 |
Why?
|
Sentinel Surveillance | 2 | 2018 | 292 | 0.620 |
Why?
|
Hemorrhagic Fever, Ebola | 3 | 2021 | 424 | 0.620 |
Why?
|
Monkeypox virus | 3 | 2023 | 43 | 0.610 |
Why?
|
Decision Support Systems, Clinical | 4 | 2022 | 1178 | 0.610 |
Why?
|
Immunologic Tests | 1 | 2019 | 101 | 0.600 |
Why?
|
Vancomycin | 3 | 2018 | 504 | 0.590 |
Why?
|
Health Facilities | 4 | 2024 | 578 | 0.590 |
Why?
|
Drug Resistance, Multiple, Bacterial | 2 | 2020 | 592 | 0.590 |
Why?
|
Polymerase Chain Reaction | 4 | 2015 | 6066 | 0.580 |
Why?
|
DNA Primers | 1 | 2021 | 2826 | 0.560 |
Why?
|
Klebsiella pneumoniae | 1 | 2019 | 253 | 0.550 |
Why?
|
Ventilator-Induced Lung Injury | 1 | 2018 | 135 | 0.550 |
Why?
|
Delivery of Health Care | 10 | 2024 | 5367 | 0.530 |
Why?
|
Hypersensitivity | 3 | 2021 | 1168 | 0.530 |
Why?
|
Viral Vaccines | 2 | 2021 | 596 | 0.530 |
Why?
|
Massachusetts | 10 | 2023 | 8890 | 0.520 |
Why?
|
Humans | 99 | 2024 | 766812 | 0.520 |
Why?
|
Ventilators, Mechanical | 1 | 2018 | 292 | 0.510 |
Why?
|
Hepatitis B | 1 | 2021 | 710 | 0.510 |
Why?
|
Pneumonia, Staphylococcal | 1 | 2015 | 39 | 0.500 |
Why?
|
Influenza A Virus, H3N2 Subtype | 1 | 2015 | 85 | 0.500 |
Why?
|
Preoperative Care | 2 | 2021 | 2253 | 0.490 |
Why?
|
Mass Screening | 4 | 2020 | 5454 | 0.480 |
Why?
|
Pneumonia, Viral | 4 | 2020 | 3232 | 0.480 |
Why?
|
Vancomycin Resistance | 2 | 2012 | 125 | 0.480 |
Why?
|
Disease Transmission, Infectious | 1 | 2020 | 560 | 0.470 |
Why?
|
Herpes Simplex | 2 | 2024 | 470 | 0.470 |
Why?
|
Workplace | 1 | 2020 | 873 | 0.450 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2021 | 949 | 0.430 |
Why?
|
Patient Transfer | 2 | 2017 | 789 | 0.420 |
Why?
|
Epidemiologic Methods | 1 | 2018 | 1326 | 0.420 |
Why?
|
Antibiotic Prophylaxis | 1 | 2018 | 641 | 0.410 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2020 | 2183 | 0.370 |
Why?
|
Hepatitis C | 1 | 2021 | 1595 | 0.370 |
Why?
|
Meningitis, Viral | 1 | 2011 | 49 | 0.370 |
Why?
|
Nasal Mucosa | 1 | 2014 | 416 | 0.350 |
Why?
|
Carrier State | 1 | 2014 | 530 | 0.350 |
Why?
|
Influenza, Human | 2 | 2015 | 1543 | 0.340 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2013 | 614 | 0.300 |
Why?
|
Pain | 1 | 2022 | 5098 | 0.280 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 1 | 2011 | 551 | 0.250 |
Why?
|
United States | 18 | 2024 | 72945 | 0.250 |
Why?
|
Models, Theoretical | 1 | 2017 | 3563 | 0.240 |
Why?
|
Patient Admission | 1 | 2012 | 1364 | 0.240 |
Why?
|
Physicians | 1 | 2022 | 4591 | 0.230 |
Why?
|
Wrestling | 1 | 2024 | 19 | 0.230 |
Why?
|
Nafcillin | 2 | 2014 | 23 | 0.230 |
Why?
|
Data Collection | 3 | 2024 | 3321 | 0.220 |
Why?
|
Hospital Design and Construction | 1 | 2024 | 34 | 0.220 |
Why?
|
Patients' Rooms | 1 | 2024 | 63 | 0.220 |
Why?
|
Cefazolin | 2 | 2014 | 94 | 0.220 |
Why?
|
Clostridium Infections | 2 | 2022 | 563 | 0.220 |
Why?
|
Electronic Health Records | 5 | 2022 | 4880 | 0.220 |
Why?
|
Methicillin Resistance | 2 | 2015 | 198 | 0.210 |
Why?
|
Facility Design and Construction | 1 | 2024 | 86 | 0.210 |
Why?
|
Needlestick Injuries | 1 | 2023 | 71 | 0.210 |
Why?
|
Industry | 1 | 2005 | 362 | 0.200 |
Why?
|
Boston | 7 | 2021 | 9346 | 0.200 |
Why?
|
Practice Guidelines as Topic | 6 | 2021 | 7430 | 0.200 |
Why?
|
Vaccination | 4 | 2021 | 3435 | 0.200 |
Why?
|
Anus Diseases | 1 | 2022 | 53 | 0.200 |
Why?
|
Herpesvirus 2, Human | 2 | 2015 | 191 | 0.200 |
Why?
|
Nucleic Acid Amplification Techniques | 2 | 2021 | 335 | 0.200 |
Why?
|
Travel | 2 | 2020 | 806 | 0.200 |
Why?
|
Catheter-Related Infections | 2 | 2015 | 279 | 0.190 |
Why?
|
Financing, Government | 1 | 2005 | 473 | 0.190 |
Why?
|
Infectious Disease Transmission, Professional-to-Patient | 1 | 2021 | 33 | 0.180 |
Why?
|
Ulcer | 1 | 2022 | 203 | 0.180 |
Why?
|
Marburg Virus Disease | 1 | 2020 | 11 | 0.180 |
Why?
|
Female | 29 | 2023 | 396532 | 0.180 |
Why?
|
Respiratory Insufficiency | 2 | 2022 | 1241 | 0.180 |
Why?
|
Risk Assessment | 4 | 2023 | 24299 | 0.170 |
Why?
|
Contact Tracing | 1 | 2022 | 274 | 0.170 |
Why?
|
Male | 27 | 2024 | 364154 | 0.170 |
Why?
|
Burn Units | 1 | 2020 | 143 | 0.160 |
Why?
|
Patient Positioning | 1 | 2022 | 332 | 0.160 |
Why?
|
Odds Ratio | 3 | 2021 | 9661 | 0.160 |
Why?
|
Colistin | 1 | 2019 | 46 | 0.160 |
Why?
|
Quality Control | 1 | 2021 | 834 | 0.160 |
Why?
|
Urinary Tract Infections | 2 | 2015 | 804 | 0.160 |
Why?
|
Bacteremia | 2 | 2016 | 987 | 0.160 |
Why?
|
Infection Control Practitioners | 1 | 2018 | 12 | 0.160 |
Why?
|
Herpesvirus 1, Human | 1 | 2024 | 743 | 0.150 |
Why?
|
Drug Resistance, Microbial | 1 | 2021 | 832 | 0.150 |
Why?
|
Crohn Disease | 1 | 2011 | 2286 | 0.150 |
Why?
|
Drug Eruptions | 1 | 2021 | 335 | 0.150 |
Why?
|
Genome, Viral | 1 | 2021 | 674 | 0.150 |
Why?
|
Influenza Vaccines | 1 | 2005 | 780 | 0.150 |
Why?
|
Retrospective Studies | 14 | 2023 | 81657 | 0.150 |
Why?
|
Amoxicillin | 1 | 2019 | 179 | 0.140 |
Why?
|
Inpatients | 6 | 2019 | 2566 | 0.140 |
Why?
|
Clindamycin | 1 | 2018 | 138 | 0.140 |
Why?
|
Rectum | 1 | 2022 | 897 | 0.140 |
Why?
|
Staphylococcus aureus | 2 | 2016 | 1429 | 0.140 |
Why?
|
Immunization | 1 | 2021 | 1218 | 0.140 |
Why?
|
Lung | 1 | 2015 | 10068 | 0.140 |
Why?
|
Medication Therapy Management | 1 | 2018 | 131 | 0.140 |
Why?
|
Plasmids | 1 | 2022 | 2268 | 0.140 |
Why?
|
Intensive Care Units | 3 | 2020 | 3799 | 0.140 |
Why?
|
Adult | 18 | 2022 | 223305 | 0.140 |
Why?
|
Workflow | 1 | 2021 | 859 | 0.140 |
Why?
|
Research | 1 | 2005 | 1977 | 0.140 |
Why?
|
Syndrome | 1 | 2023 | 3271 | 0.130 |
Why?
|
Ebolavirus | 1 | 2019 | 250 | 0.130 |
Why?
|
United States Food and Drug Administration | 1 | 2005 | 1673 | 0.130 |
Why?
|
Middle Aged | 19 | 2022 | 223267 | 0.130 |
Why?
|
Community-Acquired Infections | 1 | 2020 | 470 | 0.130 |
Why?
|
Universal Precautions | 1 | 2015 | 34 | 0.130 |
Why?
|
Aged | 17 | 2022 | 171344 | 0.120 |
Why?
|
Drug Prescriptions | 2 | 2015 | 1663 | 0.120 |
Why?
|
Microbial Sensitivity Tests | 2 | 2019 | 1972 | 0.120 |
Why?
|
Fellowships and Scholarships | 1 | 2024 | 1134 | 0.120 |
Why?
|
HIV Infections | 1 | 2021 | 17532 | 0.120 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 746 | 0.120 |
Why?
|
Safety Management | 1 | 2020 | 765 | 0.120 |
Why?
|
Prospective Studies | 6 | 2022 | 54872 | 0.120 |
Why?
|
Natural Language Processing | 1 | 2023 | 1203 | 0.120 |
Why?
|
Antibodies, Monoclonal | 1 | 2011 | 9244 | 0.110 |
Why?
|
Anaphylaxis | 1 | 2021 | 738 | 0.110 |
Why?
|
Consensus | 1 | 2024 | 3208 | 0.110 |
Why?
|
Desensitization, Immunologic | 1 | 2019 | 546 | 0.110 |
Why?
|
Shock | 1 | 2015 | 316 | 0.110 |
Why?
|
Quality Assurance, Health Care | 1 | 2023 | 2171 | 0.110 |
Why?
|
RNA, Viral | 1 | 2021 | 2867 | 0.110 |
Why?
|
Rectal Neoplasms | 1 | 2022 | 1183 | 0.110 |
Why?
|
Decision Support Techniques | 2 | 2020 | 2007 | 0.100 |
Why?
|
Cohort Studies | 8 | 2021 | 41706 | 0.100 |
Why?
|
Vaccines | 1 | 2021 | 842 | 0.100 |
Why?
|
Guidelines as Topic | 2 | 2012 | 1394 | 0.100 |
Why?
|
Allergy and Immunology | 1 | 2014 | 170 | 0.100 |
Why?
|
Immunoglobulin E | 1 | 2019 | 1495 | 0.100 |
Why?
|
Professional Competence | 1 | 2015 | 429 | 0.100 |
Why?
|
Aged, 80 and over | 8 | 2022 | 59548 | 0.100 |
Why?
|
Risk Factors | 6 | 2023 | 74889 | 0.100 |
Why?
|
Nose | 1 | 2015 | 522 | 0.100 |
Why?
|
Education, Medical, Graduate | 1 | 2024 | 2418 | 0.090 |
Why?
|
Academic Medical Centers | 2 | 2020 | 2783 | 0.090 |
Why?
|
Education | 1 | 2014 | 531 | 0.090 |
Why?
|
Integrin alpha4 | 1 | 2011 | 89 | 0.090 |
Why?
|
Fatal Outcome | 1 | 2015 | 1838 | 0.090 |
Why?
|
Drug Utilization | 1 | 2017 | 1188 | 0.090 |
Why?
|
Pregnancy | 4 | 2020 | 30236 | 0.090 |
Why?
|
Herpesvirus 3, Human | 1 | 2011 | 159 | 0.090 |
Why?
|
Communication | 1 | 2024 | 3905 | 0.080 |
Why?
|
Prevalence | 3 | 2021 | 15835 | 0.080 |
Why?
|
Drug Industry | 2 | 2007 | 791 | 0.080 |
Why?
|
RNA, Messenger | 2 | 2021 | 12795 | 0.080 |
Why?
|
Hospital Administration | 1 | 2012 | 351 | 0.080 |
Why?
|
Pneumonia | 1 | 2020 | 2161 | 0.080 |
Why?
|
Policy | 1 | 2012 | 512 | 0.080 |
Why?
|
Diagnosis, Differential | 3 | 2024 | 12985 | 0.070 |
Why?
|
Health Policy | 3 | 2024 | 2697 | 0.070 |
Why?
|
Critical Illness | 1 | 2021 | 2750 | 0.070 |
Why?
|
Containment of Biohazards | 2 | 2019 | 39 | 0.070 |
Why?
|
Hospitalization | 3 | 2022 | 10816 | 0.070 |
Why?
|
Emergency Medical Services | 1 | 2019 | 1936 | 0.070 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2018 | 1417 | 0.070 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2018 | 1389 | 0.070 |
Why?
|
Chi-Square Distribution | 1 | 2012 | 3431 | 0.060 |
Why?
|
Hospitals | 4 | 2022 | 3885 | 0.060 |
Why?
|
Malaria | 1 | 2015 | 1246 | 0.060 |
Why?
|
Plasmodium falciparum | 1 | 2015 | 1739 | 0.060 |
Why?
|
Reproducibility of Results | 2 | 2021 | 20146 | 0.060 |
Why?
|
Sensitivity and Specificity | 3 | 2019 | 14653 | 0.060 |
Why?
|
Young Adult | 4 | 2024 | 59939 | 0.060 |
Why?
|
Legislation, Food | 1 | 2005 | 17 | 0.060 |
Why?
|
Radiography | 1 | 2015 | 6968 | 0.060 |
Why?
|
Suppuration | 1 | 2024 | 60 | 0.060 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2007 | 347 | 0.060 |
Why?
|
Mupirocin | 1 | 2024 | 55 | 0.060 |
Why?
|
Software | 1 | 2018 | 4464 | 0.060 |
Why?
|
Alzheimer Disease | 1 | 2005 | 8715 | 0.050 |
Why?
|
Federal Government | 1 | 2005 | 265 | 0.050 |
Why?
|
Biomedical Research | 1 | 2019 | 3459 | 0.050 |
Why?
|
Lymphocytes | 1 | 2011 | 2606 | 0.050 |
Why?
|
Legislation, Drug | 1 | 2005 | 216 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 5536 | 0.050 |
Why?
|
Administration, Topical | 1 | 2024 | 702 | 0.050 |
Why?
|
ROC Curve | 2 | 2022 | 3621 | 0.050 |
Why?
|
Length of Stay | 1 | 2016 | 6491 | 0.050 |
Why?
|
Pilot Projects | 1 | 2015 | 8728 | 0.050 |
Why?
|
Cross Reactions | 2 | 2014 | 826 | 0.050 |
Why?
|
Predictive Value of Tests | 2 | 2022 | 15425 | 0.050 |
Why?
|
Long-Term Care | 1 | 2005 | 630 | 0.050 |
Why?
|
Prone Position | 1 | 2022 | 203 | 0.050 |
Why?
|
Policy Making | 1 | 2005 | 546 | 0.050 |
Why?
|
Marburgvirus | 1 | 2020 | 19 | 0.040 |
Why?
|
Seroepidemiologic Studies | 1 | 2022 | 404 | 0.040 |
Why?
|
Lymphocyte Activation | 1 | 2011 | 5502 | 0.040 |
Why?
|
Asia | 1 | 2021 | 629 | 0.040 |
Why?
|
Personnel, Hospital | 1 | 2021 | 285 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12064 | 0.040 |
Why?
|
Pharmaceutical Preparations | 1 | 2007 | 1086 | 0.040 |
Why?
|
Vaccines, Synthetic | 1 | 2021 | 620 | 0.040 |
Why?
|
Disaster Planning | 1 | 2024 | 558 | 0.040 |
Why?
|
Nausea | 1 | 2021 | 681 | 0.040 |
Why?
|
Medicare | 2 | 2007 | 6813 | 0.040 |
Why?
|
Area Under Curve | 1 | 2022 | 1639 | 0.040 |
Why?
|
Child | 3 | 2021 | 80670 | 0.040 |
Why?
|
Algorithms | 1 | 2018 | 14073 | 0.040 |
Why?
|
Time Factors | 2 | 2012 | 40149 | 0.030 |
Why?
|
Self Report | 2 | 2021 | 3771 | 0.030 |
Why?
|
Africa | 1 | 2019 | 725 | 0.030 |
Why?
|
Administration, Oral | 1 | 2024 | 4019 | 0.030 |
Why?
|
Outpatients | 2 | 2014 | 1596 | 0.030 |
Why?
|
Information Dissemination | 1 | 2024 | 1142 | 0.030 |
Why?
|
Cost of Illness | 1 | 2005 | 1949 | 0.030 |
Why?
|
Public Health Practice | 1 | 2017 | 219 | 0.030 |
Why?
|
Public Health Administration | 1 | 2017 | 242 | 0.030 |
Why?
|
Resource Allocation | 1 | 2017 | 354 | 0.030 |
Why?
|
Liberia | 1 | 2015 | 176 | 0.030 |
Why?
|
Internship and Residency | 1 | 2015 | 5943 | 0.030 |
Why?
|
Hypotension | 1 | 2021 | 887 | 0.030 |
Why?
|
Employment | 1 | 2021 | 1110 | 0.030 |
Why?
|
Models, Organizational | 1 | 2018 | 548 | 0.030 |
Why?
|
Risk Management | 1 | 2018 | 558 | 0.030 |
Why?
|
Intubation, Intratracheal | 1 | 2022 | 1359 | 0.030 |
Why?
|
Epidemics | 1 | 2019 | 516 | 0.030 |
Why?
|
Reference Values | 1 | 2020 | 4914 | 0.030 |
Why?
|
RNA | 1 | 2023 | 2715 | 0.030 |
Why?
|
Caregivers | 1 | 2005 | 2303 | 0.030 |
Why?
|
Incidence | 2 | 2021 | 21527 | 0.030 |
Why?
|
Documentation | 1 | 2019 | 914 | 0.030 |
Why?
|
Animals | 2 | 2021 | 168939 | 0.030 |
Why?
|
Standard of Care | 1 | 2017 | 569 | 0.030 |
Why?
|
Professional Practice | 1 | 2014 | 314 | 0.020 |
Why?
|
Europe | 1 | 2019 | 3430 | 0.020 |
Why?
|
Public Health | 1 | 2005 | 2680 | 0.020 |
Why?
|
Societies, Medical | 1 | 2024 | 3957 | 0.020 |
Why?
|
Linear Models | 1 | 2022 | 5873 | 0.020 |
Why?
|
Medicaid | 1 | 2005 | 2836 | 0.020 |
Why?
|
Cesarean Section | 1 | 2020 | 1418 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2024 | 3070 | 0.020 |
Why?
|
Interprofessional Relations | 1 | 2017 | 998 | 0.020 |
Why?
|
Hospitals, Teaching | 1 | 2015 | 1156 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2022 | 2727 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2022 | 3213 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2005 | 8045 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2023 | 2662 | 0.020 |
Why?
|
Fever | 1 | 2015 | 1607 | 0.020 |
Why?
|
Oxygen | 1 | 2019 | 4252 | 0.020 |
Why?
|
Headache | 1 | 2015 | 1260 | 0.020 |
Why?
|
Malaria, Falciparum | 1 | 2015 | 1075 | 0.020 |
Why?
|
Disease Progression | 1 | 2024 | 13642 | 0.020 |
Why?
|
Formularies as Topic | 1 | 2007 | 93 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2019 | 5344 | 0.020 |
Why?
|
Immunologic Factors | 1 | 2014 | 1594 | 0.010 |
Why?
|
Cardiac Surgical Procedures | 1 | 2020 | 3683 | 0.010 |
Why?
|
Body Mass Index | 1 | 2022 | 13050 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2021 | 22248 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2024 | 65286 | 0.010 |
Why?
|
Prognosis | 1 | 2022 | 29959 | 0.010 |
Why?
|
Costs and Cost Analysis | 1 | 2007 | 1667 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26309 | 0.010 |
Why?
|
Models, Statistical | 1 | 2015 | 5092 | 0.010 |
Why?
|
Models, Biological | 1 | 2015 | 9464 | 0.010 |
Why?
|
Adolescent | 1 | 2022 | 88902 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2014 | 39312 | 0.010 |
Why?
|